



health

Department:
Health
REPUBLIC OF SOUTH AFRICA

Private Bag X828, PRETORIA, 0001, Civitas Building, Pretoria

TO:

**HEADS OF DEPARTMENT
HEADS OF PHARMACEUTICAL SERVICES
CHIEF DIRECTORS: RESPONSIBLE FOR HIV**

NOTICE: USE OF FIXED DOSE COMBINATIONS FOR FIRST AND SECOND LINE ANTIRETROVIRAL TREATMENT REGIMENS

There are four fixed dose combination (FDC) antiretroviral (ARV) products available on HP13-2015ARV: Supply and Delivery of Antiretroviral Medicines April 2015 – March 2018:

- Abacavir (ABC) 600mg + Lamividine (3TC) 300mg
- Tenofovir (TDF) 300mg + Emtricitabine (FTC) 200mg
- Tenofovir (TDF) 300mg + Emtricitabine (FTC) 200mg + Efavirenz (EFV) 600mg
- Zidovudine (AZT) 300mg + Lamivudine (3TC) 150mg

All clinically eligible patients on first and second line adult ARV regimens should be utilising the available FDCs as follows in accordance with National Antiretroviral Treatment (ART) guidelines:

First Line Regimens			
Indication	Regimen	Fixed dose combination product/s to be used for this regimen	Addition of single ARVs to FDC combination
Preferred 1st line regimen	TDF + 3TC or FTC + Efavirenz (EFV)	TDF + FTC + Efavirenz (EFV) FDC combination	None
Contraindication to Efavirenz (EFV)	TDF + 3TC or FTC + Nevirapine (NVP)	TDF + FTC FDC combination	NVP
Contraindication to Tenofovir (TDF)	AZT + 3TC + Efavirenz (EFV)	AZT + 3TC FDC combination	EFV
Contraindication to Tenofovir (TDF) + Abacavir (ABC)	AZT + 3TC + Nevirapine (NVP)	AZT + 3TC FDC combination	NVP
Contraindication to Tenofovir (TDF) + Abacavir (ABC) + Zidovudine (AZT)	Abacavir (ABC) + 3TC + Efavirenz (EFV)	Abacavir (ABC) + 3TC FDC combination	EFV
Contraindication to Tenofovir (TDF) + Abacavir (ABC) + Zidovudine (AZT) + Nevirapine (NVP)	Abacavir (ABC) + 3TC + Nevirapine (NVP)	Abacavir (ABC) + 3TC FDC combination	NVP

Note

- This notice does not apply to patients with clinical indications requiring doses not covered by the available fixed dose combinations.
- The use of Nevirapine in pregnancy should be avoided.

Second Line Regimens			
Indication	Regimen	Fixed dose combination product/s to be used for this regimen	Addition of single ARVs to FDC combination
Failing a TDF-based first-line regimen	AZT + 3TC + LPV/r	AZT + 3TC FDC combination	LPV/r
Failing a TDF-based first-line regimen + if HBV co-infected	AZT + TDF + 3TC + LPV/r	AZT + 3TC FDC combination	TDF + LPV/r
		TDF + FTC FDC combination	AZT + LPV/r
Failing a D4T or AZT-based first-line regimen	TDF + 3TC or FTC + LPV/r	TDF + FTC FDC combination	TDF + 3TC + LPV/r
Patients with anaemia and renal failure	ABC + 3TC + LPV/r	ABC + 3TC FDC combination	LPV/r

TDF – Tenofovir, FTC – Emtricitabine, EFV – Efavirenz, NVP – Nevirapine, 3TC – Lamivudine, AZT – zidovudine, ABC – Abacavir, LPV/r – Lopinavir/Ritonavir, ATV/r – Atazanavir/Ritonavir, D4T – Stavudine

Note

- Patients unable to tolerate LPV/r should be switched to ATV/r:
 - ATV/r is part of a second line regimen not requiring specialist motivation;
 - ATV/r is not a combination product therefore both single agents of atazanavir and ritonavir are required.

Provinces and Health Care Facilities are requested to:

- Distribute and communicate this information in consultation with Pharmaceutical and Therapeutics Committees;
- Consult the National Antiretroviral Treatment Guidelines for comprehensive guidance on all regimens.

Comments and queries may be submitted to:

Ms Letta Seshoka
Tel: 012 395 9041
E-mail: seshal@health.gov.za

Dr Janine Jugathpal
Tel: 012 395 8449
E-mail: munsaj@health.gov.za
Fax to email: 086 433 0046
E-mail: SAEDP@health.gov.za

Kind regards

DR T PILLAY
DEPUTY DIRECTOR: HEALTH REGULATION AND COMPLIANCE
DATE: 25/05/2015

DR Y PILLAY
DEPUTY DIRECTOR: HIV AND AIDS, TUBERCULOSIS, AND MATERNAL AND CHILD HEALTH
DATE 35/5/15